Siklos (hydroxyurea) Disease Interactions
There are 5 disease interactions with Siklos (hydroxyurea):
Hydroxyurea (Includes Siklos) ↔ Myelosuppression
Severe Potential Hazard, Moderate plausibility
Applies to: Bleeding, Bone Marrow Depression/Low Blood Counts, Fever
The use of hydroxyurea is contraindicated in patients with marked myelosuppression. Hydroxyurea induces myelosuppression, primarily leukopenia. Thrombocytopenia and anemia occur less frequently. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Hydroxyurea should not be administered if the white blood cell count falls below 2500/mm3 and/or the platelet count falls below 100,000/mm3, or in the presence of severe anemia.
References
- "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb, Princeton, NJ.
Hydroxyurea (Includes Siklos) ↔ Renal Dysfunction
Severe Potential Hazard, High plausibility
Applies to: Renal Dysfunction
Hydroxyurea is primarily eliminated by the kidney. Approximately 80% of urea is excreted in the urine as unchanged drug or urea. Patients with marked renal impairment (CrCl < 60 mL/min or ESRD) may be at increased risk of toxicity associated with administration of hydroxyurea. Therapy with hydroxyurea should be administered cautiously to patients with compromised renal function.
References
- "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb, Princeton, NJ.
Hydroxyurea (Includes Siklos) ↔ Hepatic Dysfunction
Moderate Potential Hazard, Moderate plausibility
Applies to: Liver Disease
There are no data supporting specific guidance for hydroxyurea dosage adjustment in patients with hepatic impairment. Caution and close monitoring is advised in these patients.
Hydroxyurea (Includes Siklos) ↔ Seizure Disorders
Moderate Potential Hazard, Low plausibility
Applies to: Seizures
Seizures have been noted very rarely during hydroxyurea therapy. Therapy with hydroxyurea should be administered cautiously in patients with seizure disorders.
References
- "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb, Princeton, NJ.
Hydroxyurea (Includes Siklos) ↔ Neurologic Disorders
Minor Potential Hazard, Low plausibility
Applies to: Psychosis
Neurological symptoms such as disorientation or hallucinations have been reported very rarely during hydroxyurea therapy. Therapy with hydroxyurea should be administered cautiously to patients with or predisposed to neurological disorders.
References
- "Product Information. Hydrea (hydroxyurea)." Bristol-Myers Squibb, Princeton, NJ.
Siklos (hydroxyurea) drug Interactions
There are 184 drug interactions with Siklos (hydroxyurea)
See Also
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No information available. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
